Description: Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
Home Page: www.initiatorpharma.com
Ole Maaloes vej 3
Copenhagen,
2200
Denmark
Phone:
45 61 26 00 35
Officers
| Name | Title |
|---|---|
| Dr. Claus Elsborg Olesen | Co-Founder, CEO & Director |
| Dr. Dan Peters | Co-Founder & CTO |
| Prof. Ulf Simonsen Ph.D. | Co-Founder, CMO & CSO |
| Dr. Mikael Thomsen M.Sc., Ph.D. | Co-Founder & CDO |
| Dr. Torgeir Vaage | Chief Financial Officer |
| Dr. Allan Wehnert | Sr. VP of Clinical and R&D Strategy & Portfolio Management |
| Susanne Thomsen | Head of Clin Ops |
| Rene Egebro | Head of CMC |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 9.8135 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6364 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |